

## **Early Cardio-Renal Benefits Tomorrow Starts With Early Intervention** **Today: Role Of SGLT2i**

**Sponsored by Astra Zeneca**

During this 45-minute plenary session, Dr Vijaya will start by identifying the common features of a typical diabetic patient in Malaysia, and also highlight the extent of their cardio-renal risks. By recognizing the quintessential phenotype and understanding their inherent risks, the objective is to then identify the traits of an ideal diabetes medication that can help to address these features.

Next, Dr Vijaya will examine whether any of the currently established glucose lowering therapies has the necessary traits to be the ideal antidiabetic agent that can help our typical diabetic patients and will focus on the latest class of antidiabetic medication - the SGLT2 inhibitors. The efficacy of the SGLT2 inhibitors, beyond just glycemic control, and its safety profile will be visited in detail based on the latest evidence. The talk will end after a whistle-stop tour of the latest international guidelines.

During the course of this talk, Dr Vijaya plans to challenge some of the traditional concepts of diabetes management - like giving superfluous priority to HBA1c reduction and using metformin as a first line medication for even high risk diabetic patients, which Dr Vijaya feels is simply out of date and lacks evidence.

**Dr. Vijaya Bharath Ramasamy**